Intensive BP Treatment Appears Safe, Well Tolerated

Share this content:
Intensive BP Treatment Appears Safe, Well Tolerated
Intensive BP Treatment Appears Safe, Well Tolerated

THURSDAY, Aug. 24, 2017 (HealthDay News) -- For patients at increased risk of cardiovascular disease, intensive blood pressure control may be just as safe as standard treatment, and is likely cost-effective, according to a study published in the Aug. 24 issue of the New England Journal of Medicine.

Dan Berlowitz, M.D., M.P.H., chief of staff at the Edith Nourse Rogers Memorial Veterans Hospital in Bedford, Mass., and colleagues used information collected from 9,361 patients during the SPRINT trial. At the start of the study and then yearly, patients completed standard surveys on day-to-day well-being. They rated their physical and mental health, satisfaction with their care, and ability to adhere to their medication.

On average, the researchers found, patients on intensive treatment fared as well as those on standard care. That was true even among elderly, frail patients.

A second study in the same journal issue looked at cost. Researchers used a mathematical model to estimate the costs of additional blood pressure medication, extra doctor visits, and treatment for any adverse effects of intensive blood pressure control. They weighed that against the potential savings from prevention of cardiovascular disease events. The investigators found that intensive treatment cost well below $50,000 for every quality-adjusted life-year gained.

Abstract/Full Text 1 (subscription or payment may be required)
Abstract/Full Text 2 (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »